Free Trial

Citius Pharmaceuticals (CTXR) Competitors

Citius Pharmaceuticals logo
$1.93 -0.18 (-8.53%)
Closing price 04:00 PM Eastern
Extended Trading
$1.96 +0.03 (+1.55%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CTXR vs. INCR, IGMS, IMUX, IZTC, IKNA, MNOV, ADAP, ICCC, VHAQ, and CLSD

Should you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include InterCure (INCR), IGM Biosciences (IGMS), Immunic (IMUX), Invizyne Technologies (IZTC), Ikena Oncology (IKNA), MediciNova (MNOV), Adaptimmune Therapeutics (ADAP), ImmuCell (ICCC), Viveon Health Acquisition (VHAQ), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical products" industry.

Citius Pharmaceuticals vs. Its Competitors

Citius Pharmaceuticals (NASDAQ:CTXR) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Citius Pharmaceuticals currently has a consensus price target of $53.00, suggesting a potential upside of 2,646.11%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Citius Pharmaceuticals is more favorable than InterCure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Citius Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.80
InterCure
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

InterCure's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Citius PharmaceuticalsN/A -58.63% -37.67%
InterCure N/A N/A N/A

InterCure has higher revenue and earnings than Citius Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Citius PharmaceuticalsN/AN/A-$39.14MN/AN/A
InterCure$64.55MN/A-$18.32MN/AN/A

Citius Pharmaceuticals has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, InterCure has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500.

16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 10.7% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Citius Pharmaceuticals had 5 more articles in the media than InterCure. MarketBeat recorded 5 mentions for Citius Pharmaceuticals and 0 mentions for InterCure. InterCure's average media sentiment score of 0.00 beat Citius Pharmaceuticals' score of -0.33 indicating that InterCure is being referred to more favorably in the news media.

Company Overall Sentiment
Citius Pharmaceuticals Neutral
InterCure Neutral

Summary

Citius Pharmaceuticals beats InterCure on 8 of the 13 factors compared between the two stocks.

Get Citius Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CTXR vs. The Competition

MetricCitius PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$22.39M$2.39B$5.47B$8.95B
Dividend YieldN/A1.80%5.25%4.06%
P/E RatioN/A8.9827.0020.10
Price / SalesN/A729.50435.75120.29
Price / CashN/A159.8036.8257.86
Price / Book0.194.517.985.56
Net Income-$39.14M$31.26M$3.16B$248.40M
7 Day Performance1.58%5.57%3.69%6.04%
1 Month Performance126.79%5.48%2.91%7.69%
1 Year Performance-87.17%1.14%34.30%20.97%

Citius Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CTXR
Citius Pharmaceuticals
2.4183 of 5 stars
$1.93
-8.5%
$53.00
+2,646.1%
-84.1%$22.39MN/A0.0020News Coverage
INCR
InterCure
N/A$1.47
-1.3%
N/A-34.8%$66.99M$66.28M0.00350High Trading Volume
IGMS
IGM Biosciences
4.3971 of 5 stars
$1.12
+3.7%
$5.50
+391.1%
-78.5%$66.95M$2.68M-0.34190
IMUX
Immunic
2.7918 of 5 stars
$0.70
-0.4%
$11.60
+1,563.1%
-29.2%$66.83MN/A-0.5770Positive News
IZTC
Invizyne Technologies
N/A$10.39
+6.8%
N/AN/A$64.96MN/A0.0029Gap Up
IKNA
Ikena Oncology
2.7912 of 5 stars
$1.34
-1.5%
$3.00
+123.9%
-18.7%$64.67M$9.16M-1.5670Positive News
MNOV
MediciNova
1.832 of 5 stars
$1.31
-1.5%
$7.00
+434.4%
-11.3%$64.26M$1M-5.7010Gap Down
ADAP
Adaptimmune Therapeutics
2.1081 of 5 stars
$0.24
-2.2%
$1.35
+463.9%
-80.2%$63.53M$179.64M-0.89490Gap Up
ICCC
ImmuCell
0.2911 of 5 stars
$6.96
+3.1%
N/A+52.6%$62.92M$26.49M-99.4170
VHAQ
Viveon Health Acquisition
N/A$11.00
flat
N/AN/A$62.26MN/A0.002High Trading Volume
CLSD
Clearside Biomedical
2.0335 of 5 stars
$0.80
+3.9%
$4.75
+493.8%
-36.3%$62.17M$3.76M-1.9530News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:CTXR) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners